JNJ-61610588 (Onvatilimab) is a fully human IgG1κ anti‐VISTA antibody that is currently evaluated for safety and efficacy in advanced cancer patients, acting via traditional antibody blockade of VISTA signaling [318]. This evidence concerns the gene VSIR and cancer.